GISAID suspended researcher accounts in 2023 and revoked Open Access designation

The Global Initiative on Sharing All Influenza Data (GISAID) was the primary platform for COVID-19 genomic surveillance, with submissions from over 200 countries and territories and over 16.5 million SARS-CoV-2 sequences as of 2024.

In 2023, GISAID suspended individual researcher accounts after publications critical of the platform's origin narrative — including the Scripps group that flagged a discrepancy in the original SARS-CoV-2 submission and the international team that published the Wuhan market origin analysis. In 2025, GISAID terminated data feeds to critical surveillance tools including Nextstrain, Outbreak.info, and CoV-Spectrum. The research data repository registry re3data subsequently reclassified the platform from open-access to restricted-access (S-0039).

The case is C-0020's "governance turning adversarial" pattern at the platform that hosted the most consequential infectious-disease genomic surveillance dataset of the decade. The technology continued to operate; the governance, centralized under a single founder, determined which parts of its user community lost access for which reasons.

GISAID is the §6.2 counterpoint to INSDC: identical technical capability, opposite governance pattern. The contrast establishes that Tier 2 resilience depends on the consortium operating correctly under transparent governance, and that single-organization centralization within Tier 2 carries the same vulnerability the paper attributes to Tier 1.